CLINICAL_TRIALS
trial_result
· 2019-09-17
Clinical Trial Update: CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris [Phase 3]
Summary
Long-term safety study of trifarotene (CD5789) in acne vulgaris completed; results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Galderma R&D | Conditions: Acne Vulgaris | Phase 3 | Status: COMPLETED | Results posted: 2019-09-17